Expert Shares Rationale for GSI Plus CAR T-Cell Combination in Myeloma
February 13th 2020Andrew J. Cowan, MD, explains the rationale for a phase I clinical trial in which a gamma-secretase inhibitor was combined with CAR T-cell therapy as treatment for heavily pretreated patients with multiple myeloma.